Abstract

Dr. Lambert highlights, in this brief communication, the need to adjust PRO assessments and strategies in oncology trials to the evolving era of cancer care and the development of personalized medicine. Innovative approaches, including qualitative interviews, are becoming essential to complement data from legacy questionnaires to document patient-perceived treatment experience and benefits.